Group 1 - The company announced a commercialization service agreement with Haisen Bio, effective December 11, 2025, allowing the company to provide CSO services in China [1] - The board believes that this agreement will create synergies in regions and customer groups not fully covered by Haisen Bio, enhance product lifecycle management, and generate recurring service fee income from CSO services [1] - The company expects to leverage its existing infrastructure, sales team, and key customer relationships to create incremental sales and improve the scale, experience, and efficiency of its commercial organization [1] Group 2 - The company has also entered into an exclusive licensing agreement with Haisen Bio, granting limited rights to develop, commercialize, and sell licensed compounds and products in the specified region [1] - Mr. Sun Xin has been appointed as a non-executive director, effective December 11, 2025 [2]

Group 1 - Company entered into a commercialization service agreement with Haisen Bio, effective December 11, 2025, to provide CSO services in China [1] - The agreement aims to create synergies in regions and customer groups not fully covered by Haisen Bio, enhancing product lifecycle management and commercialization capabilities [1] - The company expects to generate recurring service fee income from CSO services, improving the utilization and productivity of its existing commercial platform [1] Group 2 - An exclusive, non-transferable license agreement was established with Haisen Bio, allowing the company to develop, commercialize, and sell licensed compounds and products in the designated region [1] - The agreement includes limited rights to sublicense based on the licensor's patents and proprietary technology [1] Group 3 - Mr. Sun Xin has been appointed as a non-executive director, effective December 11, 2025 [2]